|
|
| | PF-6260933 Basic information |
| Product Name: | PF-6260933 | | Synonyms: | PF-6260933;[3,3'-Bipyridine]-6,6'-diamine, 5-(4-chlorophenyl)-;PF06260933;PF 06260933;PF06260933;PF6260933;PF 6260933;PF-6260933;inhibit,MAP4K,MAPK Kinase Kinase Kinase,PF 06260933,PF06260933,Inhibitor,PF-06260933 | | CAS: | 1811510-56-1 | | MF: | C16H13ClN4 | | MW: | 296.75 | | EINECS: | | | Product Categories: | | | Mol File: | 1811510-56-1.mol |  |
| | PF-6260933 Chemical Properties |
| Boiling point | 483.8±40.0 °C(Predicted) | | density | 1.330±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 1 mg/ml; DMSO: 1 mg/ml; Ethanol: insol; PBS (pH 7.2): insol | | form | A solid | | pka | 5.04±0.13(Predicted) |
| | PF-6260933 Usage And Synthesis |
| Biological Activity | PF-6260933 is a MAP4K4 inhibitor with IC50 of 3.7 nM and good kinome selectivity. | | in vitro | PF-06260933 treatment of human aortic endothelial cell (EC) robustly prevents TNF-α-mediated endothelial permeability in vitro , similar to MAP4K4 knockdown. < b> | | in vivo | In the mice model, PF-06260933 treatment does not alter plasma lipid content, although reductions in glucose levels are observed, which is consistent with whole-body-inducible Map4k4 knockout animals. PF-06260933 administration ameliorates further plaque development and/or promotes plaque regression in this animal model (46.0% versus 25.5%), and a reduction in plasma glucose as well as lipid content is also observed. p> | | target | | Target | Value | MAP4K4
() | 3.7 nM |
|
| | PF-6260933 Preparation Products And Raw materials |
|